Stonegate Investment Group LLC Has $504,000 Position in Sanofi (NASDAQ:SNY)

Stonegate Investment Group LLC grew its position in Sanofi (NASDAQ:SNY) by 62.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,751 shares of the company’s stock after acquiring an additional 3,377 shares during the period. Stonegate Investment Group LLC’s holdings in Sanofi were worth $504,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Stablepoint Partners LLC raised its stake in Sanofi by 0.8% in the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after acquiring an additional 189 shares during the period. TCTC Holdings LLC raised its position in shares of Sanofi by 28.0% in the first quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after purchasing an additional 210 shares during the period. HB Wealth Management LLC lifted its stake in shares of Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after buying an additional 221 shares during the last quarter. Insigneo Advisory Services LLC boosted its holdings in shares of Sanofi by 3.3% during the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after buying an additional 228 shares during the period. Finally, Pinnacle Bancorp Inc. grew its stake in Sanofi by 24.6% in the 3rd quarter. Pinnacle Bancorp Inc. now owns 1,227 shares of the company’s stock valued at $71,000 after buying an additional 242 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SNY shares. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Up 0.1 %

Shares of SNY stock opened at $54.93 on Friday. The stock has a 50 day simple moving average of $56.11 and a 200 day simple moving average of $51.53. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a market cap of $139.12 billion, a P/E ratio of 27.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.95 EPS. On average, research analysts predict that Sanofi will post 4.26 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.